Outlook Therapeutics Inc. (OTLK)
Outlook Therapeutics Inc. (OTLK) Stock Price, Analysis & Data
| Bid | 0.83 |
| Market Cap | 205.7M |
| Revenue (ttm) | 333.14K |
| Net Income (ttm) | -60.96M |
| Beta | 0.80 |
| EPS (ttm) | -1.13 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.88 |
| P/B (ttm) | -3.97 |
| P/S (ttm) | 617.45 |
| Earnings Date | Aug 14, 2026 |
| Ask | 1.18 |
| Volume | 5,728,071 |
| Avg. Volume (20D) | 22,340,677 |
| Open | 1.12 |
| Previous Close | 1.13 |
| Day's Range | 1.07 - 1.18 |
| 52-Week Range | 0.16 - 3.39 |
| Analyst | n/a |
| Price Target | 5 (354.55%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has col...
Financial Performance
In 2025, Outlook Therapeutics's revenue was 1.41M, an increase of undefined% compared to the previous year's 0. Earnings were -62.42M, a decrease of -17.17%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for OTLK stock is "null". The 12-month stock price forecast is 5, which is upside of 354.55% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
